ADC Therapeutics SA (ADCT)
NYSE: ADCT · Real-Time Price · USD
3.750
+0.110 (3.02%)
Mar 31, 2026, 4:00 PM EDT - Market closed
ADC Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts that cover ADC Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $7.75, which forecasts a 106.67% increase in the stock price over the next year. The lowest target is $5.00 and the highest is $10.
Price Target: $7.75 (+106.67%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ADC Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 4 | 4 | 4 | 4 | 4 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $7 → $8 | Strong Buy | Maintains | $7 → $8 | +113.33% | Mar 23, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $8 → $7 | Strong Buy | Maintains | $8 → $7 | +86.67% | Oct 16, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +166.67% | Aug 13, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $8 → $5 | Buy | Maintains | $8 → $5 | +33.33% | Jun 20, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $7 → $10 | Strong Buy | Maintains | $7 → $10 | +166.67% | Jun 13, 2025 |
Financial Forecast
Revenue This Year
78.78M
from 81.36M
Decreased by -3.17%
Revenue Next Year
132.57M
from 78.78M
Increased by 68.29%
EPS This Year
-1.10
from -1.12
EPS Next Year
-0.70
from -1.10
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 92.3M | 147.6M | |||
| Avg | 78.8M | 132.6M | |||
| Low | 69.5M | 114.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 13.5% | 87.4% | |||
| Avg | -3.2% | 68.3% | |||
| Low | -14.6% | 45.8% |
EPS Forecast
| EPS | 2026 | 2027 |
|---|---|---|
| High | -0.92 | -0.58 |
| Avg | -1.10 | -0.70 |
| Low | -1.30 | -1.06 |
EPS Growth
| EPS Growth | 2026 | 2027 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.